GcMAF: Unlicensed HIV drug ‘nearly killed patient’

GcMAF: Unlicensed HIV drug ‘nearly killed patient’

GcMAF: Unlicensed HIV drug ‘nearly killed patient’

GcMAF Unlicensed HIV drug 'nearly killed patient'

David Noakes said 10,000 people had received the product with 99% having no side effects

Up to 75% of patients who reported taking an unlicensed drug marketed as a cure for autismHIV and cancer, suffered side effects, a court heard.

One of 17 customers wrote she “almost died numerous times” in feedback read at Southwark Crown Court.

The patients were taking an unlicensed blood product sold by Guernsey-based Immuno Biotech.

Founder David Noakes, of Kent, admitted selling the drug, but maintained “99%” of customers suffered no side effects.

Noakes, 65, of Waldershare, Dover, pleaded guilty to charges of manufacturing, supplying and selling the unlicensed medicine and money laundering. He is expected to be sentenced next week.

‘Almost died’

He told a Newton hearing, held before a judge alone to resolve issues disputed by the defence and prosecution, his firm had treated 10,000 people.

Only four of the 17 patients did not complain of side effects after taking the human blood-based product – said to be derived from GcMAF, a cancer therapy treatment, the judge was told.

One customer said she went into “toxic shock” and “almost died numerous times”, with two ambulance trips and “endless ER visits”.

Others described headaches, nausea, and abdominal pain, side effects Noakes described as “negligible” for people suffering “complicated” ailments.

Sixty-five per cent of people taking GcMAF improved, he added, rising to 85% if they took 10 or more vials of the product.

Latest news and stories from the Channel Islands

On Wednesday, the court heard from a member of a self-help group for people with chronic fatigue syndrome based in Chester.

Joan Crawford, a chartered chemical engineer, told the court about half of the 16 members who took GcMAF in 2012 experienced positive changes, while a quarter experienced no change, and just “a couple” felt worse in the short-term.

During the hearing Noakes defended GcMAF as a treatment for a number of conditions, but on Tuesday said he no longer claims it cures cancer.

Creative Commons Disclosure

This news article was published by BBC News Click here to see the original post.

About the Mandatory Training Group

The Mandatory Training Group is the leading UK provider of accredited healthcare and social care statutory and mandatory training courses, programs and qualifications.

Click on the links below to find out more about our drug dosage calculations training courses

Contact our Support Team on 02476100090 or via Email for more courses relating to the Care Quality Commission (CQC) and other regulatory compliance requirements.

GcMAF: Unlicensed HIV drug ‘nearly killed patient’

Share this post

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.


%d bloggers like this: